MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, October 9, 2009

Fampridine-SR Update - for the proposed indication of improvement of walking ability in people with multiple sclerosis (MS).

Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR
  • Company to Host Investor Conference Call on Thursday, October 15 at 8:00 a.m.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 9, 2009-- Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Peripheral and Central Nervous System Drugs Advisory Committee meeting to review Acorda’s New Drug Application (NDA) for Fampridine-SR for the proposed indication of improvement of walking ability in people with multiple sclerosis (MS). The Prescription Drug User Fee Act (PDUFA) action date for the Fampridine-SR NDA is October 22, 2009.

The Advisory Committee meeting is scheduled for 8:00 a.m. ET on Wednesday, October 14th. The briefing materials can be accessed at:

Continue Reading this news release


No comments: